Browse recruiting and upcoming clinical trials for stiff person syndrome.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIAdults with Progressive Multiple Sclerosis, Neuromyelitis Optica, MOG antibody‑associated disease, autoimmune encephalitis, or Stiff‑Person Syndrome.
What is being studied AITests the safety and preliminary efficacy of CTX112, an anti‑CD19 allogeneic CAR‑T cell therapy.
Who can join AIPeople with Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), Autoimmune Encephalitis, or Stiff Person Syndrome.
What is being studied AITests a single IV infusion of autologous CD20/BCMA-directed CAR-T cells (C-CAR168).
Who can join AIAdults 18–80 with selected autoimmune diseases (including lupus nephritis, SLE, systemic sclerosis, AAV, idiopathic inflammatory myopathies, or stiff person syndrome).
What is being studied AITests safety and dosing of ADI-001 (prula-cel) CAR-engineered T cells.
Who can join AIAdults (≥18) with Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis, Multiple Sclerosis, Dermatomyositis, or Systemic Sclerosis who previously received KYV-101.
What is being studied AICollects long-term safety and persistence data after KYV-101 CAR T-cell treatment.